Shopping Cart No items
Call toll-free : 1-877-385-8998
Friday 8 May 2020
Myrbetriq (mirabegron) is a prescription medication that's used to treat overactive bladder.
But who manufactures Myrbetriq, when was it approved and how is it used today? Read on to learn everything you need to know about the history of Myrbetriq.
Myrbetriq is manufactured by Astellas Pharma Inc., a Tokyo-based pharmaceutical company formed in 2005 with the merging of two long-standing Japanese drug companies. One was founded in 1923, and the other was founded in 1894.
In the years following its inception, Astellas Pharma quickly grew to become a multinational corporation.
Today, the company's U.S. headquarters are located in Northbrook, Illinois, where about 1,200 people are employed.
Astellas Pharma manufactures a variety of drugs for several therapeutic areas, including:
At the time of writing, Astellas Pharma markets a total of 12 drugs in the United States. Besides Myrbetriq, the company's other noteworthy medications include Prograf (tacrolimus), Vesicare (solifenacin) and Cresemba (isavuconazonium sulfate).
Mirabegron, the active ingredient in Myrbetriq, was first submitted for approval by the Food and Drug Administration (FDA) in 2011.
As a beta-3 adrenergic agonist, Myrbetriq was and is the only OAB medication in its class that targets the beta-3 pathway, a nerve pathway made up of beta 3 receptors in the bladder.
By targeting beta 3 receptors, Myrbetriq is able to relax the smooth muscle surrounding the bladder, giving the bladder an increased ability to store urine.
The FDA officially approved Myrbetriq for OAB in 2012. In 2018, the FDA also approved Myrbetriq to be used in conjunction with another medication (solifenacin succinate) to treat symptoms of OAB.
According to data compiled by ClinCalc in 2020, mirabegron is the 191st most-prescribed drug in the U.S., with more than three million prescriptions written as of 2017.
As with any other drug, Myrbetriq has the potential to cause both minor and serious side effects. According to the official Myrbetriq website, possible serious side effects include:
At the time of writing, there is no generic version of Myrbetriq available in the U.S. The earliest time at which a generic equivalent may become available is March 27, 2022, at which point the drug's patent will expire.
Until then, patients can save money on their Myrbetriq prescription by purchasing it from a reputable online pharmacy or verified pharmacy referral service like My Drug Center.
Buy Myrbetriq online now and have it shipped right to your door.
Weekdays: 9:00 AM - 6:00 PM PSTWeekends: 10:00 AM - 03:00 PM PST